BACKGROUND: It has been proposed that the Borna Disease Virus (BDV) plays a role in the etiopathogenesis of psychiatric disorders. We assessed BDV seropositivity in Polish psychiatric patients and healthy controls, and the relationship between seropositivity and selected diagnostic and clinical variables. MATERIAL/ METHODS: Serum samples from 946 psychiatric patients with different diagnoses (ICD-10) and 407 psychiatrically healthy controls were assayed. The ECLIA method was used, which enables the assessment of two anti-BDV antibodies: anti-p24 and anti p-40. Data were also collected on diagnosis, age, age at onset, and place of residence. RESULTS: Only anti-p24 antibodies were found. The seropositivity rates were: 2.4% and 1.0%, respectively, in patients and controls (p=0.1). A significant difference between patients and controls was observed in mental retardation and affective-anxiety spectrum disorders. Seropositivity did not show any association with demographic variables, but it was elevated in patients with recent onset of disease vs. remote onset of disease (10.2% vs. 1.6%; p=0.0003). CONCLUSIONS: Significantly higher anti-BDV seropositivity was found in Polish psychiatric patients with affective-anxiety spectrum disorders and mental retardation than in controls. The association between recent onset disorders and higher anti-BDV response, in the light of recent reports on circulating immune complexes of BDV antigens and antibodies, warrants further studies on the longitudinal course of humoral response to BDV.
BACKGROUND: It has been proposed that the Borna Disease Virus (BDV) plays a role in the etiopathogenesis of psychiatric disorders. We assessed BDV seropositivity in Polish psychiatricpatients and healthy controls, and the relationship between seropositivity and selected diagnostic and clinical variables. MATERIAL/ METHODS: Serum samples from 946 psychiatricpatients with different diagnoses (ICD-10) and 407 psychiatrically healthy controls were assayed. The ECLIA method was used, which enables the assessment of two anti-BDV antibodies: anti-p24 and anti p-40. Data were also collected on diagnosis, age, age at onset, and place of residence. RESULTS: Only anti-p24 antibodies were found. The seropositivity rates were: 2.4% and 1.0%, respectively, in patients and controls (p=0.1). A significant difference between patients and controls was observed in mental retardation and affective-anxiety spectrum disorders. Seropositivity did not show any association with demographic variables, but it was elevated in patients with recent onset of disease vs. remote onset of disease (10.2% vs. 1.6%; p=0.0003). CONCLUSIONS: Significantly higher anti-BDV seropositivity was found in Polish psychiatricpatients with affective-anxiety spectrum disorders and mental retardation than in controls. The association between recent onset disorders and higher anti-BDV response, in the light of recent reports on circulating immune complexes of BDV antigens and antibodies, warrants further studies on the longitudinal course of humoral response to BDV.